Friday, March 05, 2010 12:00:13 PM
No News yet since the Bad News Bomb. As mentioned in the PR's there is more coming soon. I'm sure the company is working together a PR to help shoot this back up. Remember they own shares too and don't want their stock this low. I think we should expect something next week.
Recent CLRB News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 12:23:46 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/04/2026 12:21:32 PM
- Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates • GlobeNewswire Inc. • 03/04/2026 12:15:00 PM
- Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 • GlobeNewswire Inc. • 02/25/2026 01:05:00 PM
- Cellectar Biosciences Expands Global Intellectual Property Estate • GlobeNewswire Inc. • 02/17/2026 01:05:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/13/2026 09:44:33 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/10/2026 08:23:12 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/04/2026 09:11:14 PM
- Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference • GlobeNewswire Inc. • 01/09/2026 01:05:00 PM
- Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies • GlobeNewswire Inc. • 12/16/2025 01:05:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/21/2025 09:05:22 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 11/14/2025 03:46:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 12:30:56 PM
- Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/13/2025 12:20:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 12:00:58 PM
- Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025 • GlobeNewswire Inc. • 11/06/2025 01:05:00 PM
- Cellectar Biosciences stock jumps after FDA grants Rare Pediatric Disease Designation • IH Market News • 10/27/2025 02:48:22 PM
- Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma • GlobeNewswire Inc. • 10/27/2025 12:30:00 PM
- Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research • GlobeNewswire Inc. • 10/14/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2025 08:30:38 PM
- Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million • GlobeNewswire Inc. • 10/07/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2025 11:15:48 AM
- Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM) • GlobeNewswire Inc. • 10/06/2025 11:00:00 AM
- Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer • GlobeNewswire Inc. • 09/30/2025 12:30:00 PM
- Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC) • GlobeNewswire Inc. • 09/24/2025 12:30:00 PM
